Enanta Positive Results of EPD-305 for NASH
Enanta (ENTA) has positive results from the ARGON-1 Phase 2 study evaluating the safety, tolerability pharmacokinetics and efficacy of its product EPD-305 for the treatment of non-alcoholic steatohepatitis (NASH).
The results met the primary endpoint of ALT reduction at week 12; in the . . .